15 results about "Prevention infection" patented technology

The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.

The present disclosure relates to compositions comprising lipid nanoparticles (LNPs) configured for targeting dendritic cells. In particular, the present disclosure provides LNPs comprising a serine-based helper-lipid, a PEG lipid, an ionizable lipid, a cholesterol component, and one or more nucleic acids. The present disclosure provides use of the LNPs for the delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in various therapeutics, such as for the treatment of cancer or autoimmune diseases or prevention of infectious diseases. Finally, methods are provided for preparing such LNPs.

The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5′ copy-back DI-RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV (wt-MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5′ copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and / or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture.

The present disclosure relates to nucleic acid molecules comprising 5'-UTR and / or 3'-UTR sequences that result in high levels of translation. Aspects of the present disclosure further relate to nucleic acid molecules suitable for use as vaccines in the treatment and prevention of infectious diseases, including those caused by coronaviruses, compositions comprising the nucleic acid molecules, and methods of treating or preventing infectious diseases.

The invention belongs to the technical field of preparation of vaccine immunologic adjuvants, and discloses a surface-modified aluminum hydroxide nanoparticle adjuvant as well as preparation and application thereof. The aluminum hydroxide-based adjuvant is a next-generation aluminum hydroxide-based adjuvant at an optimal level specially optimized for veterinary vaccines. The formula of the adjuvant solves the limitation of the traditional aluminum hydroxide adjuvant, including poor cellular immune induction and variable efficacy in large animals. The adjuvant promotes balanced Th1 / Th2 immune response, reduces local injection site reaction, and improves the shelf life of the vaccine. The preparation method comprises ultrasonic homogenization and co-precipitation under pH control, vaccine compositions containing the adjuvant, and uses of the adjuvant in prevention of infectious diseases in animal husbandry, companion animals and poultry. Experimental data show that in bovine respiratory disease and avian influenza models, compared with traditional adjuvants, the immunogenicity is excellent, the antibody titer is increased by 3 times, and CD8 + T cell response is enhanced.

The present invention relates to a composition for use in treating or preventing a respiratory infection in a subject, the composition comprising plasma and immunoglobulins against a causative agent of the respiratory infection, the immunoglobulins being obtained from a donor subject who has developed a humoral immune response against the causative agent of the respiratory infection, and the composition being administered intranasally, and optionally orally. The invention further relates to a nasal, nasopharyngeal, or oronasal spray device comprising such a composition, and a nasal, nasopharyngeal, or oronasal spray comprising plasma and immunoglobulins against the causative agent of the respiratory infection, the immunoglobulins being obtained from a donor subject who has developed a humoral immune response against the causative agent of the respiratory infection.

The present disclosure provides immunogenic compositions, such as vaccines, including DNA vaccines, and uses thereof, for example, including annexin core domains for mediating effective antigen delivery and antigen presentation to induce antigen-specific immune responses, and / or to treat or prevent infectious diseases and / or cancer.

Provided herein are pharmaceutical compositions that include a pharmaceutically active agent, a cellulose nanocrystal or a cellulose nanofiber, a thermogelling biocompatible polymer, and a gelling agent. Such pharmaceutical compositions can be configured as a bioink suitable for 3D printing. Such pharmaceutical compositions are suitable for treating bone disorders, including osteoporosis. Methods of treating Paget's disease, treating or preventing cancer, treating or preventing an infectious disease, and treating or preventing a disorder through regenerative medicine are also provided.

The present disclosure relates to an mRNA molecule encoding a polypeptide comprising an hMPV F protein, or an immunogenic fragment thereof, and a lumazine synthase (LuS) capable of multimerising to form a nanoparticle. Further aspects of the disclosure relate to compositions comprising the mRNA molecule and their use as a vaccine in the prevention of infectious diseases, including those caused by hMPV and RSV.

The present invention relates to self-amplifying RNA (saRNA) vaccines against infectious laryngotracheitis (ILT) that provide safe and effective prophylactic and therapeutic immune responses and improve the symptoms of the disease. In particular, the invention relates to sRNAs encoding at least one laryngotracheitis virus polypeptide, an ILTV polypeptide variant, or an immunogenic fragment or epitope thereof, said sRNA comprising a first nucleic acid sequence comprising nsP1, nsP2, nsP3 and nsP4 which encode non-structural alphavirus proteins, a second nucleic acid sequence encoding at least one ILTV polypeptide, an ILTV polypeptide variant, an immunogenic fragment or an epitope thereof, and also comprising a 5' cap, a 5' UTR upstream of the first nucleic acid sequence, a 26S promoter upstream of the second nucleic acid sequence, a 3' UTR and a poly A tail.The sRNA according to the present invention allows, when incorporated into a cell, the expression of at least one ILTV polypeptide, an ILTV polypeptide variant, or an immunogenic fragment or an epitope of one of them.

Infectious diseases continue to burden populations around the world. Both naturally occurring and engineered biological threats hold increasing potential to cause disease, disability, and death. The liposomes comprise a targeting molecule that binds a target antigen expressed by a pathogen, wherein the targeting molecule is a C-Type Lectin polypeptide or a fragment thereof comprising a carbohydrate recognition domain (CRD), wherein the targeting molecule is incorporated into the outer surface of the liposome. Provided herein are targeted nanoparticle compositions and methods for the diagnosis, treatment or prevention of an infectious disease using same.

Provided herein are methods for preparing macrobicyclic thiolincosamines and associated synthetic intermediates. These routes allow access to lincosamide analogues, which are useful for the treatment and prevention of infectious diseases. The methods are scalable and provide access to multi-gram quantities of the aminooctose (northern) fragments of the lincosamide analogues.

The present invention relates to the use of uroporphyrin I (UROI) or a pharmaceutically acceptable salt or metal complex thereof for the treatment and / or prevention of transmissible spongiform encephalopathies (TSEs) or prion diseases.

The invention relates to an infectious disease identification, automatic reporting and automatic tracking method, and relates to the technical field of medical information extraction. The identification model of the preset infectious disease is trained based on the plurality of medical records in which the preset infectious disease is found earliest, so that whether the new patient suffers from the preset infectious disease or not can be identified based on the diagnosis and treatment information of the new patient, the identification of the preset infectious disease is quickly realized, and the identification efficiency is improved on the basis of the identification. The preset infectious diseases are automatically reported and tracked, and the tracking efficiency of reporting of the preset infectious diseases is improved, so that timely early warning and early prevention are realized, and the satisfaction level of management targets of early screening, early treatment and early prevention of the infectious diseases is improved.

The present invention relates to a composition for use in the treatment or prevention of a respiratory infectious disease in a subject, wherein said composition comprises blood plasma and immunoglobulins directed against a causative agent of said respiratory infectious disease, wherein said immunoglobulins are obtained from a donor subject who has developed a humoral immune response to said causative agent of said respiratory infectious disease; and wherein said composition is administered intranasally, and optionally orally. The present invention further relates to a nasal, naso-oropharyngeal, or oro-nasal spray device comprising such composition and a nasal, naso-oropharyngeal, or oro-nasal spray comprising blood plasma and immunoglobulins directed against a causative agent of said respiratory infectious disease, wherein said immunoglobulins are obtained from a donor subject who has developed a humoral immune response to said causative agent of said respiratory infectious disease.